Morepen Laboratories Ltd. — Investor Presentation 2021

May 4, 2021

==> picture [96 x 791] intentionally omitted <==

==> picture [42 x 64] intentionally omitted <==

==> picture [124 x 30] intentionally omitted <==

Date: 04/05/2021

To,

National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288

Subject: Investors Presentation (Q4’FY21) May, 2021

Dear Sir,

Please find enclosed the Investors Presentation (Q4’FY21) May, 2021 , based on the financial performance of the Company for the quarter and financial year ended 31[st] March, 2021.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

==> picture [170 x 72] intentionally omitted <==

Encl.: As Above

Morepen Laboratories Limited

Corp. Off.: 4[th] Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi- 110 001, INDIA Tel.:+91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website:www.morepen.com CIN NO. L24231 HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205 Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com

MOREPEN

LABORATORIES LIMTED

==> picture [406 x 98] intentionally omitted <==

Q4'FY21 Investor Presentation May 2021

==> picture [638 x 810] intentionally omitted <==

Disclaimer/ Confidentiality

This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.

This presentation has been prepared by the Company based on information an data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise.

The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / advice may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.

This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.

This presentation contain confidential data and information about the company historical performance and future business plan strategy and the any reader/user can not copy, circuculate or use disclose the said information or part of it to anyone without prior written permission of the Company. Any unauthorised use of the data will attract legal action against the person.

.

==> picture [142 x 35] intentionally omitted <==

C O N S O L I D A T E D

Rs. in crores

12M'FY21

ANNUAL HIGHLIGHTS

==> picture [492 x 527] intentionally omitted <==

----- Start of picture text -----

^39% ^67%
Net Revenue E B I D T A
862.55 1200.12
78.00 130.58
^152% ^189%
Profit before Tax EPS (12M)
39.10 98.51 Rs. 0.75 Rs. 2.16
FY20 FY21 FY20 FY21
----- End of picture text -----

==> picture [96 x 78] intentionally omitted <==

==> picture [364 x 396] intentionally omitted <==

----- Start of picture text -----

^189%
Profit after Tax
33.58 97.09
FY20 FY21
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

C O N S O L I D A T E D

Rs. in crores

Q4'FY21

QUARTERLY HIGHLIGHTS

==> picture [492 x 531] intentionally omitted <==

----- Start of picture text -----

^40% ^68%
Net Revenue E B I D T A
208.39 290.76
20.61 34.56
^143% ^136%
Profit before Tax EPS (3M)
11.36 27.63 Rs. 0.25 Rs. 0.59
Q4'FY20 Q4'FY21 Q4'FY20 Q4'FY21
----- End of picture text -----

==> picture [364 x 399] intentionally omitted <==

----- Start of picture text -----

^143%
Profit after Tax
11.02 26.76
Q4'FY20 Q4'FY21
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

e q u i t y u p d a t e

MAY'21

FRESH EQUITY INFUSION

Promoters increasing stake from 34.54% to 44.28%

==> picture [417 x 211] intentionally omitted <==

----- Start of picture text -----

$32.50 MILLION
corinth group switzerland
9.41% EQUITY STAKE
----- End of picture text -----

Approved by the board on 28.4.21"

• 70 million warrants in FY21 25% - subscription received 75% - to be received within 18 months

• 50 million shares in FY22 Approved by the board on 28.4.21*

*Subject to regulatory and shareholders approvals

==> picture [191 x 18] intentionally omitted <==

----- Start of picture text -----

pre-issue holdings
----- End of picture text -----

post issue holdings

==> picture [599 x 187] intentionally omitted <==

----- Start of picture text -----

Promoters
33.5%
Promoters
44.3%
46.3%
Public
66.5%
Corinth
9.4%
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

CONSOLIDATED a n n u a l o p e r a t i o n a l p e r f o r m a n c e

Rs. in crores

12M'FY21

C O N S O L I D A T E D

REVENUE GROWTH

==> picture [371 x 410] intentionally omitted <==

----- Start of picture text -----

^40%
300
290.76
200
208.38
100
0
FY20 FY21
----- End of picture text -----

Quarterly performance

==> picture [96 x 78] intentionally omitted <==

==> picture [75 x 92] intentionally omitted <==

==> picture [602 x 659] intentionally omitted <==

----- Start of picture text -----

^39%
1,250
1200
1,000
863
750
772
610
500
250
0
FY'18 FY'19 FY'20 FY'21
25% CAGR
----- End of picture text -----

Rs. in crores

12M'FY21

C O N S O L I D A T E D ( C o m p a n y - w i d e )

==> picture [1161 x 653] intentionally omitted <==

----- Start of picture text -----

500
EXPORT REVENUE ^39%
477
400
343
300
200 312
^34%
150 171.70 236
^48% 200
100 119.06
100
50 40%
exports FY21
0
0
FY'18 FY'19 FY'20 FY'21
Export Domestic
Q4'FY21 revenue split 26% CAGR
----- End of picture text -----

EXPORT REVENUE

==> picture [142 x 35] intentionally omitted <==

==> picture [1440 x 810] intentionally omitted <==

----- Start of picture text -----

API BUSINESS MEDICAL DEVICES
FORMULATIONS OTC (SUBSIDIARY)
----- End of picture text -----

c o n s o l i d a t e d

Rs. in crores 12M'FY21

==> picture [1359 x 540] intentionally omitted <==

----- Start of picture text -----

SEGMENT WISE GROWTH
^44% ^71% -5% ^32%
750 300
150 100
682.99 287.37
137.56 131.36
500 200 75 85.55
100
473.95
168.35 50 64.73
250 100
50
25
0 0
0 0
FY20 FY21 FY20 FY21
FY20 FY21 FY20 FY21
A P I D I A G N O S T I C S FORMULATIONS DR.MOREPEN -OTC
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

s t a n d a l o n e

Rs. in crores 12M'FY21

SEGMENT WISE BREAKUP

==> picture [1348 x 496] intentionally omitted <==

----- Start of picture text -----

FY'20 FY'21
Formulations
11.9%
API
1.20%
60.8% 62.0%
Diagnostic Devices
Diagnostics
26.1% 4.50%
21.6% 26.1%
API
62%
formulations
5.70%
17.6% 11.9%
revenue split FY'21
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

API BUSINESS l e a d e r s h i p t h r o u g h q u a l i t y

Rs. in crores

12M'FY21

a p i b u s i n e s s

API REVENUE

==> picture [363 x 412] intentionally omitted <==

----- Start of picture text -----

^51%
200
171.29
150
100 113.20
50
0
Q4'FY20 Q4'FY21
----- End of picture text -----

Quarterly performance

==> picture [96 x 78] intentionally omitted <==

==> picture [470 x 611] intentionally omitted <==

----- Start of picture text -----

750
^44%
683
500
474
413
339
250
0
FY'18 FY'19 FY'20 FY'21
26% CAGR
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

Rs. in crores

12M'FY21

a p i b u s i n e s s

==> picture [96 x 78] intentionally omitted <==

API EXPORT

==> picture [640 x 428] intentionally omitted <==

----- Start of picture text -----

^48%
125
117.88
100
75
^59%
50
53.41
69%
25
exports FY21
0
Export Domestic
Q4'FY21 revenue split
----- End of picture text -----

==> picture [468 x 594] intentionally omitted <==

----- Start of picture text -----

500 ^ 39%
473
400
341
300
309
235
200
100
0
FY'18 FY'19 FY'20 FY'21
26% CAGR
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

Rs. in crores

12M'FY21

a p i b u s i n e s s

==> picture [96 x 78] intentionally omitted <==

GLOBAL CUSTOMERS

==> picture [684 x 490] intentionally omitted <==

----- Start of picture text -----

1,000
^14%
826
750
723
589
500
451
250
0 103 new customers
FY'18 FY'19 FY'20 FY'21
added in FY21
increasing customer base
----- End of picture text -----

==> picture [605 x 599] intentionally omitted <==

----- Start of picture text -----

Africa
7.9%
S. America
11.3%
USA
Asia
1.5%
40.7%
Europe 826 customers
11.1%
India
27.6%
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

Rs. in crores 12M'FY21

a p i b u s i n e s s

CONTINENT WISE GROWTH

826 customers

==> picture [1271 x 440] intentionally omitted <==

----- Start of picture text -----

^36% ^21% ^48% ^55% ^70% ^47%
75 125 300 250 40 20
200 18.92
68.22 100 107.94 251.55 202.51 30 15
50 200 31.57
150
75 89.25
50.28 12.87
170.29 20 10
50 100 131.06 18.59
25 100
10 5
25 50
0 0 0 0 0 0
FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21
12 92 336 228 93 65
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

Rs. in crores 12M'FY21

a p i b u s i n e s s

CONTINENT WISE GROWTH

==> picture [452 x 445] intentionally omitted <==

----- Start of picture text -----

750
680.71
S. Africa
S. America
USA
500 472.35 Europe
411.85
340.32
India
250
Asia
0
FY'18 FY'19 FY'20 FY'21
continent wise sales
----- End of picture text -----

==> picture [568 x 525] intentionally omitted <==

----- Start of picture text -----

Others
24.4%
India
29.7%
TOP 10
Israel
2.6%
countries
Pakistan
2.7%
Thailand
2.7%
Germany
USA
3.6%
10%
Iran
5.2%
B'desh
China
5.7% Spain 7.2%
6.2%
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

a p i b u s i n e s s

R&D CENTRE t h e b a c k b o n e o f A P I

a p i b u s i n e s s R&D CORE COMPETENCE

==> picture [920 x 488] intentionally omitted <==

----- Start of picture text -----

NON-INFRINGING NEW POLYMORPHS
development
process & patents
IMPURITY
COST EFFECTIVE
profiling
processes
----- End of picture text -----

a p i b u s i n e s s

SPECIALISED CHEMISTRY SKILLS

GRIGNARD FRIEDEL-CRAFT STEREOSELECTIVE reaction chiral reduction reaction HECK CYNATION SN2 reaction reaction reaction

one of few select indian companies carrying out highly sensitive and complex reactions at plant level since last 25 years at 3KL to 5KL reaction volume

==> picture [142 x 35] intentionally omitted <==

a p i b u s i n e s s

INTELLECTUAL PROPERTY

==> picture [135 x 64] intentionally omitted <==

==> picture [82 x 43] intentionally omitted <==

==> picture [1232 x 549] intentionally omitted <==

----- Start of picture text -----

USA
Europe
135 129
Japan
DMFs
patents
korea
China
Taiwan
Australia
30
13
new products
china idls
FY'21: 10 patent, 18 dmf, 1 IDL, 5 new products
----- End of picture text -----

API EXPANSION C A P I T A L I S I N G B I G O P P O R T U N I T Y

a p i b u s i n e s s

==> picture [96 x 78] intentionally omitted <==

APIS GOING OFF PATENT

15 blockbuster drugs going off patent in next 5 years morepen ready with generic version to launch at patent expiry

$42 BILLION market size in 2025

morepen market to grow 15 times from present $2.89 billion market 15X

50 USD billion

40

==> picture [389 x 16] intentionally omitted <==

----- Start of picture text -----

42.07
----- End of picture text -----

30 20 20.29 18.84 16.00 10 9.70 0 2021 2022 2023 2024 2025 year wise patent expiry

==> picture [142 x 35] intentionally omitted <==

a p i b u s i n e s s

API EXPANSION AT BADDI

==> picture [154 x 71] intentionally omitted <==

178 CR 3 YEARS 700 completion time new hirings project cost 40 2000 MT 4217 CR new products production value installed capacity project approved by state govt, environment clearance obtained

==> picture [142 x 35] intentionally omitted <==

==> picture [1440 x 810] intentionally omitted <==

----- Start of picture text -----

MEDICAL DEVICES
m a r k e t l e a d e r s h i p
----- End of picture text -----

Rs. in crores 12M'FY21

m e d i c a l d e v i c e s

==> picture [1260 x 698] intentionally omitted <==

----- Start of picture text -----

REVENUE GROWTH
^71%
300
287.35
^
200
75 57%
62.86 168.35
50
139.75
100
39.93 103.35
25
0
0
Q4'FY20 Q4'FY21
FY'18 FY'19 FY'20 FY'21
Quarterly performance
41% CAGR
----- End of picture text -----

REVENUE GROWTH

m e d i c a l d e v i c e s

GROWTH DRIVERS

==> picture [96 x 78] intentionally omitted <==

==> picture [997 x 337] intentionally omitted <==

----- Start of picture text -----

^51% 117%
g l u c o m e t e r s B P M o n i t o r s
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

m e d i c a l d e v i c e s

GLUCO METERS

==> picture [96 x 78] intentionally omitted <==

5 MILLION 600 MILLION m e t e r s i n s t a l l e d s t r i p s s o l d s o f a r Fy21 188 MILLION

==> picture [142 x 35] intentionally omitted <==

Fy21 1.69 MILLION

==> picture [1440 x 810] intentionally omitted <==

----- Start of picture text -----

DEVICES EXPANSION
l e a d e r s h i p i n P O C d e v i c e s
----- End of picture text -----

m e d i c a l d e v i c e s DEVICES R&D CENTRE

==> picture [96 x 78] intentionally omitted <==

scaling up R&D Team to create world class R&D Centre for medical devices in india

==> picture [1177 x 412] intentionally omitted <==

----- Start of picture text -----

CORE KEY BACKWARD
hi-tech components integration
technologies
CONNECTED DATA
QUICK
devices mining using AI and ML rapid tests
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

m e d i c a l d e v i c e s

DEVICES EXPANSION PLAN

==> picture [154 x 71] intentionally omitted <==

immediate requirements and focus the new products are proudly developed by in house R&D team

OXIMETERS OXYGEN PATIENT concentrators monitors and related devices FERTILITY RAPID TESTS PAIN pregnancy & ovulation for infectious diseases managment devices

==> picture [142 x 35] intentionally omitted <==

m e d i c a l d e v i c e s

THREE YEAR VISION

==> picture [96 x 78] intentionally omitted <==

==> picture [154 x 71] intentionally omitted <==

b a c k w a r d i n t e g r a t i o n i n t o c o r e t e c h n o l o g i e s

ENZYMES PCB/SMT MOLECULAR lines for all devices sieves & filters for In-vitro devices CONNECTED ACQUISITIONS JV PARTNERS similar products for technologies devices & data

==> picture [142 x 35] intentionally omitted <==

m e d i c a l d e v i c e s

DEVICES EXPANSION PLAN

==> picture [154 x 71] intentionally omitted <==

150 CR 2 YEARS 500 completion time new hirings project cost 10 ROBOTIC 2000 CR new products production value controls

At adjoining site at baddi only, land owned by the promoters

==> picture [142 x 35] intentionally omitted <==

FORMULATIONS b r a n d e d & g e n e r i c f o r m u l a t i o n s

Rs. in crores 12M'FY21

f o r m u l a t i o n s

GROSS REVENUE

==> picture [376 x 397] intentionally omitted <==

----- Start of picture text -----

40.o -13%
30.o 33.08
28.21
20.o
10.o
0.o
Q4'FY20 Q4'FY21
----- End of picture text -----

==> picture [96 x 78] intentionally omitted <==

==> picture [36 x 14] intentionally omitted <==

----- Start of picture text -----

200
----- End of picture text -----

==> picture [450 x 423] intentionally omitted <==

----- Start of picture text -----

150
-5%
153.17
137.57
130.73
110.51
100
50
0
FY'18 FY'19 FY'20 FY'21
----- End of picture text -----

Quarterly performance

==> picture [142 x 35] intentionally omitted <==

f o r m u l a t i o n s

E X P A N S I O N a n d a s f o r r e g u l a t e d m a r k e t s

f o r m u l a t i o n s

R&D & PRODUCT DEVP.

==> picture [96 x 78] intentionally omitted <==

==> picture [1177 x 475] intentionally omitted <==

----- Start of picture text -----

setting up formulation development centre at par with international standards
NON- INFRINGING NOVEL NOVEL
formulations polymorphic forms
processes
NDDS SUSTAINED NEW
with least drug substance release tablets combination
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

f o r m u l a t i o n s

ANDAS FOR USA MARKETS

==> picture [1177 x 502] intentionally omitted <==

----- Start of picture text -----

w o r k i n g o n 1 3 a n d a s w i t h 4 1 d i f f e r e n t s t r e n g t h s
DIABETES CARDIAC OTHERS
6 products-14 strengths 5 products-24 strengths 2 products-3 strengths
$6.25 BN $23.61 BN $ 0.76 BN
market size at expiry market size at expiry market size
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

f o r m u l a t i o n s

ANDAS FOR USA MARKETS

bench scale development lab scale development completed completed 6 PRODUCTS 2 PRODUCTS 5 PRODUCTS bench scale ready with 6m stability prototype FRML available PILOT BIO TECH-TRANSFER TECH PACK within 3 months within 3 months within 6 months

==> picture [142 x 35] intentionally omitted <==

f o r m u l a t i o n

WORLD CLASS ANDA PROJECT

100 CR 2 YEARS 300 completion time new hirings project cost 25 AUTOMATIC 2000 CR filling & packing lines new products production value At existing site at baddi only, land parcel already ear marked

==> picture [142 x 35] intentionally omitted <==

==> picture [408 x 130] intentionally omitted <==

O T C , h e a l t h & N u t r i t i o n

Rs. in crores 12M'FY21

==> picture [219 x 70] intentionally omitted <==

==> picture [1130 x 672] intentionally omitted <==

----- Start of picture text -----

GROSS REVENUE
100
^32%
85.55
25 ^ 26% 75 64.63
20 22.43 50 54.38
48.89
15 17.78
10
25
5
0
0
Q4'FY20 Q4'FY21
FY'18 FY'19 FY'20 FY'21
Quarterly performance
20% CAGR
----- End of picture text -----

GROSS REVENUE

==> picture [132 x 42] intentionally omitted <==

==> picture [219 x 70] intentionally omitted <==

HEALTH & NUTRITION

==> picture [96 x 78] intentionally omitted <==

==> picture [756 x 551] intentionally omitted <==

----- Start of picture text -----

54% 3%
health & nutrition online sales
skin collagen
immunity disinfectants sanitizers omega-3
new launches in FY21
----- End of picture text -----

==> picture [124 x 127] intentionally omitted <==

==> picture [104 x 176] intentionally omitted <==

==> picture [156 x 138] intentionally omitted <==

green tea & honey

==> picture [655 x 294] intentionally omitted <==

----- Start of picture text -----

muscle food sexuall wellness
omega-3 stress & sleep slim shake general health
----- End of picture text -----

exclusive online range launched at dr.morepen.com

==> picture [219 x 70] intentionally omitted <==

PERSONAL GROOMING

==> picture [393 x 120] intentionally omitted <==

----- Start of picture text -----

26% 26%
online sales
----- End of picture text -----

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [119 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [119 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 119] intentionally omitted <==

==> picture [113 x 114] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [118 x 119] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [112 x 112] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [118 x 119] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [118 x 119] intentionally omitted <==

==> picture [118 x 118] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [219 x 70] intentionally omitted <==

==> picture [96 x 78] intentionally omitted <==

SPECIALITY SKINCARE

==> picture [220 x 227] intentionally omitted <==

DEEP CLEANSER

==> picture [322 x 237] intentionally omitted <==

==> picture [330 x 67] intentionally omitted <==

see you soon

==> picture [80 x 13] intentionally omitted <==

----- Start of picture text -----

PROBIOTIC
----- End of picture text -----

VITAMIN-C SERUM

==> picture [325 x 237] intentionally omitted <==

BODY SCRUB

==> picture [219 x 70] intentionally omitted <==

E X P A N S I O N expanding the product basket & reach

==> picture [219 x 70] intentionally omitted <==

R&D & PRODUCT DEVP.

investing heavily on product development in various areas HEALTH NUTRACEUTICALS ENERGY products drinks & capsules & fitness products AYURVEDA HIGH-END PACKAGING with a scientific backing cosmetology innovations

==> picture [132 x 42] intentionally omitted <==

==> picture [219 x 70] intentionally omitted <==

EXPANSION PLAN

==> picture [96 x 78] intentionally omitted <==

c a p i t a l i s i n g o n t h e E q u i t y o f D r . M o r e p e n - a h o u s e h o l d b r a n d

==> picture [1177 x 412] intentionally omitted <==

----- Start of picture text -----

OTC- TRADE ONLINE GROOMING
100 products health & Nutrition 200 products available
500 1000 500
products in three years products in three years products in three years
----- End of picture text -----

==> picture [132 x 42] intentionally omitted <==

==> picture [219 x 70] intentionally omitted <==

DR. MOREPEN EXPANSION

==> picture [1177 x 412] intentionally omitted <==

----- Start of picture text -----

100 CR 2 YEARS ONLINE
completion time full ecommerce set up
project cost
BRAND SOCIAL 1000 CR
building & surveys media & reach sales value
----- End of picture text -----

==> picture [132 x 42] intentionally omitted <==

c o n s o l i d a t e d

FINANCIAL h i g h l i g h t s & r a t i o s

c o n s o l i d a t e d

Rs. in crores

Q4'FY21

FINANCIAL HIGHLIGHTS

==> picture [1359 x 340] intentionally omitted <==

----- Start of picture text -----

^40% ^36% ^68% ^143% ^143% ^143%
300 300 40
30 30 0.6
290.76
256.19 30 34.56 27.63 26.76 0.59
200 200
20 20 0.4
208.39
187.78 20
20.62
100 100 10 10 11.42 0.2 0.25
10 11.36
0 0 0 0 0
0
Q4'FY20 Q4'FY21 Q4'FY20 Q4"FY21 Q4'FY20 Q4'FY21 Q4'FY20 Q4'FY21 Q4'FY20 Q4'FY21
Q4'FY20 Q4'FY21
Net Revenue Expenditure ebitda profit before tax profit after tax eps (rs)
----- End of picture text -----

q u a r t e r l y p e r f o r m a n c e

==> picture [142 x 35] intentionally omitted <==

c o n s o l i d a t e d

Rs. in crores

12M'FY21

FINANCIAL HIGHLIGHTS

==> picture [1373 x 340] intentionally omitted <==

----- Start of picture text -----

^39% ^36% ^67% ^152% ^189% ^189%
1,250 1,250 150
100 100 2
1200.12
1,000 1,000 130.58 98.51 97.09
1069.54
75 75 1.5
100
2.16
750 862.55 750
784.55
50 50 1
78.00
500 500
50
39.11
25 25 0.5
250 250 33.58 0.75
0 0 0 0 0
0
FY20 FY21 FY20 Q4"FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21
Net Revenue Expenditure ebitda profit before tax profit after tax eps (rs)
----- End of picture text -----

a n n u a l p e r f o r m a n c e

==> picture [142 x 35] intentionally omitted <==

c o n s o l i d a t e d

OPERATING RATIOS

==> picture [96 x 78] intentionally omitted <==

Rs. in crores 12M'FY21

==> picture [1354 x 376] intentionally omitted <==

----- Start of picture text -----

-9% ^5% ^16% ^168% ^74% ^108%
2 2.5
5
25 10 10
4.88
1.82
4 4.67 2
1.5 1.66 2.06 20
7.5 8.54% 7.5 8.38%
53.71
3 1.5 1.77
15
1
20.05 5 5
2 1 10 4.92%
4.03%
0.5 2.5
1 0.5 5 2.5
0 0 0 0 0
0
FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21
debtors inventory turnover current interest coverage operating net profit
(months sales) (months) ratio ratio margin margin
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

s t a n d a l o n e

Rs. in crores 12M'FY21

BALANCE SHEET RATIOS

==> picture [1359 x 376] intentionally omitted <==

----- Start of picture text -----

---
^42% ^29% ^31% ^101% ^90%
100 400 0.5
100 25 15
89.96 89.96 0.4 607.73
75 300 0.43 20
316.16 75 21.1%
0.3 10 11.33
15
50 200 0.31
222.06 50
0.2
10
464.76 10.5% 5
25 100 25
0.1
5 5.96
0 0 0 0 0
0
FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21
equity capital reserve & surplus debt equity ratio total capital roe roce
employed
----- End of picture text -----

==> picture [142 x 35] intentionally omitted <==

Thank you